

## ***Tillæg***

til aftalen af 18/12-24 om "Review af folder om senfølger"

mellem:

Roche Pharmaceuticals A/S  
Flaskehalsen 17, 4. sal  
1799 København V

Og

Brystkræftforeningen  
c/o forperson Anja Skjoldborg Hansen  
Landlyst Vænge 46  
2635 Ishøj

Tillægget omfatter, at Brystkræftforeningen påtager sig opgaven også at reviewe Roches udkast til den patientrettede folder "Brystkræft er ikke bare Brystkræft."

Denne tillægsaftale er omfattet af de samme punkter som i kontrakten af 18/12-24, på nær nedenstående punkter, som er opdaterede og specifikke for reviewet af "Brystkræft er ikke bare Brystkræft".

### **Samarbejdsaftalens formål**

Formålet med tillægsaftalen er, at virksomheden bestiller et review hos organisationen af en patientrettet folder *"Brystkræft er ikke bare Brystkræft."* Virksomheden vil anvende dette review i sin færdiggørelse af folderen.

### **Samarbejdsprojektets navn**

Samarbejdsprojektets navn er "Review af folderen *'Brystkræft er ikke bare brystkræft'*"

### **Parternes rolle i samarbejdet**

Virksomheden forpligter sig med nærværende samarbejdsaftale til at betale organisationen for at gennemføre et review af udkast til folder.

Organisationen forpligter sig til at gennemføre reviewet og formidle sine kommentarer til virksomheden.

### **Tidsramme**

Samarbejdet, hvis nærmere formål og omfang er beskrevet ovenfor, skal afvikles fra underskrivelse af samarbejdsaftalen og indtil 14. februar 2025.

Parternes rettigheder og forpligtelser i henhold til nærværende samarbejdsaftale løber fra underskriftsdato og indtil samarbejdsaftalens forpligtelser er opfyldt, medmindre andet udtrykkeligt er aftalt.

### **Finansiel ydelse**

10.000 kr. excl. moms.

### **Offentliggørelse**

Nærværende samarbejdsaftale er beskrevet på Virksomhedens hjemmeside [www.roche.dk](http://www.roche.dk) frem til 14. februar 2027.

## 14. Underskrift

København, 05 February 2025

DocuSigned by:




90DB13A8013C4A8...

Anja Skjoldborg Hansen

*Forperson, Brystkræftforeningen*

København, 04 February 2025

Signed by:



91A12969174A416...

Poul Riese

*Patient Partnership Lead,*

Roche Pharmaceuticals a/s

04 February 2025

Signed by:



6E287418733647E...

Pia Møllgaard Mikkelsen,

*Business Lead*

Roche Pharmaceuticals a/s

DS  


## Certificate Of Completion

Envelope Id: 42CD4ADA-99BE-4DD1-AD93-1933A4CD910C  
 Subject: Complete with Docusign: Tillægssaftale\_køb af review af folder hos BF.pdf  
 Source Envelope:  
 Document Pages: 3  
 Certificate Pages: 4  
 AutoNav: Enabled  
 Envelopeld Stamping: Disabled  
 Time Zone: (UTC+01:00) Amsterdam, Berlin, Bern, Rome, Stockholm, Vienna

Status: Completed

Envelope Originator:  
 Karin Fryland  
 Grenzacherstrasse 124  
 Basel, Basel-Stadt 4070  
 karin.fryland@roche.com  
 IP Address: 196.3.50.247

## Record Tracking

Status: Original  
 2/4/2025 11:18:32 AM

Holder: Karin Fryland  
 karin.fryland@roche.com

Location: DocuSign

## Signer Events

Jacob Møller Nielsen  
 Jacob.moller\_nielsen@roche.com  
 Nordic\_408  
 Security Level: Email, Account Authentication (None)

## Signature



Signature Adoption: Pre-selected Style  
 Using IP Address: 217.74.149.80

## Timestamp

Sent: 2/4/2025 11:24:45 AM  
 Viewed: 2/4/2025 1:12:47 PM  
 Signed: 2/4/2025 1:12:54 PM

## Electronic Record and Signature Disclosure:

Accepted: 12/17/2021 1:48:06 PM  
 ID: cb7bbb02-7cf5-4335-85a0-2907741ab174  
 Company Name: F. Hoffmann-La Roche Ltd

Pia Møllgaard Mikkelsen  
 pia.mollgaard@roche.com  
 Security Level: Email, Account Authentication (None)



Signature Adoption: Pre-selected Style  
 Using IP Address: 196.3.50.248

Sent: 2/4/2025 1:12:55 PM  
 Viewed: 2/4/2025 2:59:01 PM  
 Signed: 2/4/2025 2:59:38 PM

## Electronic Record and Signature Disclosure:

Accepted: 2/4/2025 2:59:01 PM  
 ID: 64df2f88-2fd4-4bb9-b568-1b17cc05e7d0  
 Company Name: F. Hoffmann-La Roche Ltd

Poul Riese  
 poul.riese@roche.com  
 Security Level: Email, Account Authentication (None)




Signature Adoption: Pre-selected Style  
 Using IP Address: 196.3.50.248

Sent: 2/4/2025 1:12:56 PM  
 Viewed: 2/4/2025 2:19:33 PM  
 Signed: 2/4/2025 2:19:49 PM

## Electronic Record and Signature Disclosure:

Accepted: 2/4/2025 2:19:33 PM  
 ID: 8fe3c404-1f3d-4756-85cc-277e707bf898  
 Company Name: F. Hoffmann-La Roche Ltd

Anja Skjoldborg Hansen  
 ansk@brystkraeft.dk  
 President of the board  
 Security Level: Email, Account Authentication (None)



Signature Adoption: Drawn on Device  
 Using IP Address: 130.225.0.251

Sent: 2/4/2025 2:59:40 PM  
 Viewed: 2/5/2025 9:47:33 AM  
 Signed: 2/5/2025 9:47:49 AM

## Electronic Record and Signature Disclosure:

Signer Events	Signature	Timestamp
Accepted: 5/24/2024 12:56:17 PM ID: adc52752-9a62-4b36-8b8a-877bf873ba1b Company Name: F. Hoffmann-La Roche Ltd		
In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	2/4/2025 11:24:45 AM
Certified Delivered	Security Checked	2/5/2025 9:47:33 AM
Signing Complete	Security Checked	2/5/2025 9:47:49 AM
Completed	Security Checked	2/5/2025 9:47:49 AM
Payment Events	Status	Timestamps
Electronic Record and Signature Disclosure		

# **Guidelines for the use of the DocuSign electronic signing system within F. Hoffmann-La Roche and companies of the Roche Group**

## **LEGAL DISCLOSURE**

By placing my electronic signature on this document, I expressly consent to use and rely on Electronic and Digital Signatures and I understand my signature will have the same binding effect as if I was providing a handwritten signature.

I also confirm the email address that I am using as a valid one to be notified and identified electronically, for example through the DocuSign System, and/or to identify me as the signer of the document. I should inform Roche in the case that the email address changes.

## **CONSUMER DISCLOSURE**

From time to time, F. Hoffmann-La Roche and companies of the Roche Group (hereinafter referred to as we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign, Inc. (DocuSign) electronic signing system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your consent by clicking the 'I agree' button at the bottom of this document.

### **Consequences of changing your mind**

To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign 'Withdraw Consent' form on the signing page of a DocuSign envelope instead of signing it. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

### **All notices and disclosures will be sent to you electronically**

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

### **How to contact us**

You may contact us to let us know of your changes as to how we may contact you electronically, to request certain information from us and to withdraw your prior consent to receive notices and disclosures electronically. To do so contact the sender of the envelope.

### **To advise us of your new email address**

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to the sender of the envelope and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address. In addition, you must notify DocuSign, Inc. to arrange for your new email address to be reflected in your DocuSign account by following the process for changing email in the DocuSign system.

### **To withdraw your consent**

To inform us that you no longer want to receive future notices and disclosures in electronic format you may decline to sign a document from within your DocuSign session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent.

### **Acknowledging your access and consent to receive materials electronically**

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to email this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the 'I agree' button below.

By checking the 'I agree' box, I confirm that:

- I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF ELECTRONIC CONSUMER DISCLOSURES document; and
- I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
- Until or unless I notify the account owner as described above, I consent to receive from exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by the account owner during the course of my relationship with you.
- I acknowledge the information included in the† [DocuSign Privacy Policy](#)